Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications

[1]  M. Heymann,et al.  Drugs in early clinical development for the treatment of osteosarcoma , 2016, Expert opinion on investigational drugs.

[2]  Elizabeth E. Hull,et al.  HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases , 2016, BioMed research international.

[3]  Y. Huang,et al.  Histone deacetylase inhibitor sodium butyrate suppresses proliferation and promotes apoptosis in osteosarcoma cells by regulation of the MDM2–p53 signaling , 2016, OncoTargets and therapy.

[4]  C. Srisomsap,et al.  Overexpression of KH-type splicing regulatory protein regulates proliferation, migration, and implantation ability of osteosarcoma , 2016, International journal of oncology.

[5]  J. Mayerson,et al.  Osteosarcoma: A Meta-Analysis and Review of the Literature. , 2015, American journal of orthopedics.

[6]  Diana Yu,et al.  Identification of Synergistic, Clinically Achievable, Combination Therapies for Osteosarcoma , 2015, Scientific Reports.

[7]  J. Wilmott,et al.  Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma , 2015, Modern Pathology.

[8]  H. Putter,et al.  Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer , 2015, Histopathology.

[9]  M. Kwon,et al.  Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast , 2014, Journal of breast cancer.

[10]  R. Johnstone,et al.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2015, Nature Reviews Drug Discovery.

[11]  S. Lowe,et al.  Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. , 2014, Blood.

[12]  R. Johnstone,et al.  New and emerging HDAC inhibitors for cancer treatment. , 2014, The Journal of clinical investigation.

[13]  E. Kleinerman,et al.  Participation of the Fas/FasL signaling pathway and the lung microenvironment in the development of osteosarcoma lung metastases. , 2014, Advances in experimental medicine and biology.

[14]  E. Kleinerman,et al.  The Narrow-Spectrum HDAC Inhibitor Entinostat Enhances NKG2D Expression Without NK Cell Toxicity, Leading to Enhanced Recognition of Cancer Cells , 2013, Pharmaceutical Research.

[15]  W. Weichert,et al.  Radiosensitization by histone deacetylase inhibition in an osteosarcoma mouse model , 2013, Strahlentherapie und Onkologie.

[16]  E. Kleinerman,et al.  The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases. , 2013, Current cancer drug targets.

[17]  David M. Thomas,et al.  Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells , 2013, Sarcoma.

[18]  V. Thayanithy,et al.  Combinatorial Treatment of DNA and Chromatin-Modifying Drugs Cause Cell Death in Human and Canine Osteosarcoma Cell Lines , 2012, PloS one.

[19]  E. Kleinerman,et al.  MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts , 2012, Cell Death and Disease.

[20]  J. Beck,et al.  Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation , 2012, Cancer biology & therapy.

[21]  A. Fedenko,et al.  A Meta-Analysis of Osteosarcoma Outcomes in the Modern Medical Era , 2012, Sarcoma.

[22]  E. Kleinerman,et al.  Effect of the histone deacetylase inhibitor SNDX‐275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases , 2011, Cancer.

[23]  Jennifer J Westendorf,et al.  Histone deacetylases in skeletal development and bone mass maintenance. , 2011, Gene.

[24]  H. Okamura,et al.  Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity. , 2010, Oncology reports.

[25]  W. Weichert,et al.  High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo , 2009, BMC Cancer.

[26]  W. Weichert,et al.  Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer , 2008, BMC Cancer.

[27]  Carsten Denkert,et al.  Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. , 2008, The Lancet. Oncology.

[28]  P. Choong,et al.  A review of clinical and molecular prognostic factors in osteosarcoma , 2008, Journal of Cancer Research and Clinical Oncology.

[29]  D. Trouche,et al.  Cleavage and Cytoplasmic Relocalization of Histone Deacetylase 3 Are Important for Apoptosis Progression , 2006, Molecular and Cellular Biology.

[30]  A. Kim,et al.  Histone deacetylase 1-mediated histone modification regulates osteoblast differentiation. , 2006, Molecular endocrinology.

[31]  R. Cheepsattayakorn,et al.  Spectrum of bone tumors in Chiang Mai University Hospital, Thailand according to WHO classification 2002: A study of 1,001 cases. , 2006, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[32]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[33]  岡田 貴充.  Involvement of P-glycoprotein and MRP1 in resistance to cyclic tetrapeptide subfamily of histone deacetylase inhibitors in the drug-resistant osteosarcoma and Ewing's sarcoma cells , 2006 .

[34]  Y. Yoo,et al.  Mechanism of histone deacetylase inhibitor Trichostatin A induced apoptosis in human osteosarcoma cells , 2004, Apoptosis.